Glytec, a provider of insulin management software, announced $21 million in financing from Silicon Valley Bank (SVB), Savitr Capital and other private investors. The funding includes $9 million debt financing from SVB and a $12 million equity investment led by Savitr.

Glytec is an insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power a solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment, including those with and without a diagnosis of diabetes.